Patients with Post-Traumatic Stress Disorder (PTSD), a mental disorder which mostly develops in people who have experienced a shocking, scary or dangerous event could soon be cured by a drug derived from marijuana.
This is after the first patient with PTSD was enrolled for a clinical trial evaluating Nantheia ATL5, an investigational drug derived from cannabis.
Also Read: September, Suicide Prevention Awareness Month
Mathew Rizzo, the principal investigator of the drug who is from the University of Nebraska Medical Centre department of neurological sciences in the USA said the drug has been approved by the department of Food and Drug Administration (FDA).
“Our collaboration with Ananda Scientific (a research-focused biotech company) is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population,” Rizzo said.
The research uses cannabidiol, a chemical in the cannabis sativa plant, in Aanda’s propriety Liquid structure delivery technology.
